3 days popular7 days popular1 month popular3 months popular

Overcoming Drug Resistance In Cancer

Overactive epidermal growth factor receptor () signaling has been linked to the development of .

Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed resistance to these drugs and are therefore no longer responsive to drug treatment.

In a recent research article published in the , Goutham Narla and colleagues at sought to better understand the molecular players in the EGFR signaling pathway in hopes of finding new drug targets for EGFR-associated cancers.

Using cancerous human lung tissue and a mouse model of EGFR-associated , The Narla team discovered that two tumor suppressor genes, KLF6 and FOXO1, function to disrupt overactive EGFR signaling.

After treating the cancerous lung tissue and cancer-prone mice with an FDA-approved drug called trifluoperazine hydrochloride (TFP), which increases the activity of FOXO1, they restored the effectiveness of the anti-EGFR drug erlotinib and reduced tumor growth.

Their work identified new drug targets for EGFR-associated cancers and suggests that combinatorial regimens may improve treatment outcome.

TITLE: Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response

http://www.jci.org/articles/view/62058?key=9eb9f31baf7df0c3365e

Source

Journal of Clinical Investigation